ADXS - Advaxis Inc Stock Price, Fair Value and News

0.14USD0.00 (0.00%)Market Closed

Market Summary

USD0.140.00

Market Closed

0.00%

ADXS Stock Price

View Fullscreen

ADXS RSI Chart

ADXS Valuation

Market Cap

6.0M

Price/Earnings (Trailing)

-0.13

Price/Sales (Trailing)

491.92

EV/EBITDA

-0.19

Price/Free Cashflow

-0.22

ADXS Price/Sales (Trailing)

ADXS Profitability

Operating Margin

-26869.23%

EBT Margin

-399876.92%

Return on Equity

-4.8K%

Return on Assets

-289.96%

Free Cashflow Yield

-461.3%

ADXS Fundamentals

ADXS Revenue

Revenue (TTM)

13.0K

Rev. Growth (Yr)

-100%

Rev. Growth (Qtr)

-100%

ADXS Earnings

Earnings (TTM)

-48.1M

Earnings Growth (Qtr)

-236.19%

Breaking Down ADXS Revenue

Last 7 days

-28.6%

Last 30 days

-40%

Last 90 days

-73.7%

Trailing 12 Months

-83.3%

How does ADXS drawdown profile look like?

ADXS Financial Health

Current Ratio

0.3

Debt/Equity

8.07

Debt/Cashflow

-3.62

ADXS Investor Care

Shares Dilution (1Y)

793.27%

Diluted EPS (TTM)

-11.36

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	522.3K	352.5K	182.8K	13.0K
2022	3.0M	2.4M	1.3M	250.0K
2021	3.7M	3.8M	3.8M	3.2M
2020	0	14.0M	7.1M	253.0K
2019	12.0M	15.0M	17.9M	20.9M
2018	10.3M	8.6M	6.7M	6.1M
2017	7.5M	11.0M	14.0M	12.0M
2016	1.3M	250.0K	250.0K	4.0M
2014	0	672.3K	836.2K	1.0M
2010	0	0	269.1K	508.5K
2009	0	0	0	29.7K

Get all data in R, Python etc through our Historical Stock Data APIs

About Advaxis Inc

Ayala Pharmaceuticals, Inc., a clinical-stage oncology company, primarily focuses on developing and commercializing small molecule therapeutics for people living with rare tumors and aggressive cancers. It is also developing proprietary Lm-based antigen delivery products for patients suffering from common cancers. The company's lead candidates under development are AL102, which targets the aberrant activation of the Notch pathway with gamma secretase inhibitors to treat various tumors, including desmoid tumors; and ADXS-504, a Lm-based therapy for early-stage prostate cancer. Ayala Pharmaceuticals, Inc. was founded in 2017 and is based in Monmouth Junction, New Jersey.

CEO	Mr. Kenneth A. Berlin J.D.
WEBSITE	ayalapharma.com
INDUSTRY	Biotechnology

Advaxis Inc Frequently Asked Questions

What is the ticker symbol for Advaxis Inc? What does ADXS stand for in stocks?

ADXS is the stock ticker symbol of Advaxis Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Advaxis Inc (ADXS)?

As of Thu Jul 25 2024, market cap of Advaxis Inc is 5.97 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ADXS stock?

You can check ADXS's fair value in chart for subscribers.

Is Advaxis Inc a good stock to buy?

The fair value guage provides a quick view whether ADXS is over valued or under valued. Whether Advaxis Inc is cheap or expensive depends on the assumptions which impact Advaxis Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ADXS.

What is Advaxis Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu Jul 25 2024, ADXS's PE ratio (Price to Earnings) is -0.13 and Price to Sales (PS) ratio is 491.92. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ADXS PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Advaxis Inc's stock?

In the past 10 years, Advaxis Inc has provided -0.397 (multiply by 100 for percentage) rate of return.